IP Verse

Methods For Treating Hepcidin-Mediated Disorders - EP3329018

The patent EP3329018 was granted to Astrazeneca Pharmaceuticals on Mar 31, 2021. The application was originally filed on Jul 28, 2016 under application number EP16833574A. The patent is currently recorded with a legal status of "Revoked".

EP3329018

ASTRAZENECA PHARMACEUTICALS
Application Number
EP16833574A
Filing Date
Jul 28, 2016
Status
Revoked
Nov 23, 2024
Grant Date
Mar 31, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANDec 24, 2021MURGITROYDADMISSIBLE

Patent Citations (2) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTUS2016017056
OPPOSITIONWO2018144773

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
INTERNATIONAL-SEARCH-REPORT- SONG et al., "Down-regulation of hepcidin resulting from long-term treatment with an anti- IL -6 receptor · antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease", Blood., (20100000), vol. 116, no. 18, pages 3627 - 3634, XP055362309 [Y] 1-4, 66B, 67B, 68-71 * ; abstract, pg 3629, col 2, para 2-3, pg 3632, col 2, para 3, Table 1, Fig. 3 *
INTERNATIONAL-SEARCH-REPORT- NAI et al., "TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in I normal individuals", Blood, (20110000), vol. 118, no. 16, pages 4459 - 4462, XP055362310 [Y] 1-4, 66B, 67B, 68-71 * ; abstract, pq 4460, col 2, para 2-3 *
OPPOSITION- RAJ, "Role of Interleukin-6 in the Anemia of Chronic Disease", Seminars in Arthritis and Rheumatism, (20090000), vol. 38, doi:10.1016/j.semarthrit.2008.01.006, pages 382 - 388, XP026069925
OPPOSITION- Chambers John C, Et Al, "Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels", Nature Genetics, Nature Publishing Group US, New York, New York, (20091101), vol. 41, no. 11, doi:10.1038/ng.462, ISSN 1061-4036, pages 1170 - 1172, XP055879255
OPPOSITION- Rossi J-F, Et Al, "A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer", British Journal of Cancer, Nature Publishing Group UK, London, London, (20101001), vol. 103, no. 8, doi:10.1038/sj.bjc.6605872, ISSN 0007-0920, pages 1154 - 1162, XP055879261
OPPOSITION- Lee Pauline, "Role of Matriptase-2 (TMPRSS6) in Iron Metabolism", ACTA HAEMATOLOGICA, S. KARGER, BASEL, CH, CH , (20090101), vol. 122, no. 2-3, doi:10.1159/000243792, ISSN 0001-5792, pages 87 - 96, XP055879248
OPPOSITION- SONG et al., "Down-regulation of hepcidin resulting from long-term treatment with an anti- IL -6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease", Blood, (20100000), vol. 116, doi:10.1182/blood-2010-03-271791, pages 3627 - 3634, XP055362309
OPPOSITION- NA I et al., "TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals", Blood, (20110000), vol. 118, doi:10.1182/blood-2011-06-364034, pages 4459 - 4462, XP055362310
OPPOSITION- SCHIPPERUS et al., "CNT0328 (Anti- IL -6 mAb) treatment is associated with an increase in hemoglobin (Hb) and decrease in hepcidin levels in renal cell carcinoma (RCC", Blood, (20090000), vol. 114, doi:10.1182/blood.V114.22.4045.4045, XP086690268
OPPOSITION- PELUSI et al., "The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis", BMC Nephrology, (20130200), vol. 14, doi:10.1186/1471-2369-14-48, XP021141149
OPPOSITION- ISAACS et al., "Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis", Arthritis Research & Therapy, (20130000), vol. 15, doi:10.1186/ar4397, page R204, XP021171864
OPPOSITION- De Falco L. et al, "Iron refractory iron deficiency anemia", Haematologica, Fondazione Ferrata Storti, IT, IT , (20130601), vol. 98, no. 6, doi:10.3324/haematol.2012.075515, ISSN 0390-6078, pages 845 - 853, XP055879250
OPPOSITION- Maura Poli et al, "Hepcidin antagonists for potential treatments of disorders with hepcidin excess", Frontiers in Pharmacology, vol. 5, doi:10.3389/fphar.2014.00086, pages 1 - 13, XP055486712
OPPOSITION- Keskin Ebru Yılmaz, Yenicesu İdil, "Iron-Refractory Iron Deficiency Anemia", TURKISH JOURNAL OF HAEMATOLOGY, TURKISH SOCIETY OF HAEMATOLOGY, ISTANBUL, TR, TR , (20150305), vol. 32, no. 1, doi:10.4274/tjh.2014.0288, ISSN 1300-7777, pages 1 - 14, XP055879254
SEARCH- MISATO HASHIZUME ET AL, "Tocilizumab, a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production", RHEUMATOLOGY INTERNATIONAL ; CLINICAL AND EXPERIMENTAL INVESTIGATIONS, SPRINGER, BERLIN, DE, (20090729), vol. 30, no. 7, ISSN 1437-160X, pages 917 - 923, XP019801014 [A] 1-17 * abstract *
SEARCH- E. FUNG ET AL, "Manipulation of the hepcidin pathway for therapeutic purposes", HAEMATOLOGICA, (20131101), vol. 98, no. 11, doi:10.3324/haematol.2013.084624, ISSN 0390-6078, pages 1667 - 1676, XP055170100 [A] 1-17 * page 1670, column l, paragraph 2 - page 1670, column r, paragraph 1; table 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents